Razoxane (ICRF-159), PDGF beta-receptor inhibitor (ab145979)

Overview

  • Product name

    Razoxane (ICRF-159), PDGF beta-receptor inhibitor
  • Description

    Potent, cell-permeable, reversible, ATP-competitive PDGF β-receptor inhibitor. Topoisomerase II inhibitor.
  • Alternative names

    • ICRF-159
  • Biological description

    Potent, cell-permeable, reversible, ATP-competitive PDGF β-receptor inhibitor. Topoisomerase II inhibitor. Shows antiangiogenic, antimetastatic and antiproliferative and antitumor effects in vivo. Orally active.
  • Purity

    > 98%
  • CAS Number

    21416-67-1
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Vavrova A  et al. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One 8:e76676 (2013). Read more (PubMed: 24116135) »
  • Lu DY  et al. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol 5:11 (2005). Read more (PubMed: 15963241) »
  • Herman EH  et al. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159). Cancer Chemother Pharmacol 19:277-81 (1987). Read more (PubMed: 3594714) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab145979.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up